Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

April 17, 2018
Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings

April 4, 2018
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 5, 2018
Sage Therapeutics to Present at Cowen & Co. 38th Annual Health Care Conference

Read More News

Associated Team Members

Kevin Starr
Partner